Rome Therapeutics
Executives
View the org chart displaying its 17 main executives
Most searched biographies at Rome Therapeutics
- Rosana Kapeller, President, Chief Executive Officer and Director
- Jeff Hatfield, Chairman of the Board
- Steven Kafka, Director
Popular executive movements at Rome Therapeutics
- Heike Keilhack has joined the company as Chief Scientific Officer (posted on January 5 2024).
- Kyle Kuvalanka has joined the company as Chief Financial Officer and Chief Business Officer (posted on October 5 2023).
Create your alert
to follow the executive moves at Rome Therapeutics.
Biotechnology
Rome Therapeutics has 2,289 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Adaptive Phage Therapeutics (United States (USA)).
Popular M&A news in Biotechnology
- Lycia Therapeutics has just announced a $107 Million fundraising (posted on May 15 2024).
- Attovia Therapeutics has just announced a $150 Million fundraising (posted on May 14 2024).
- Bruker has announced the acquisition of NanoString Technologies (posted on May 13 2024).
Popular contacts in Biotechnology
News
Press releases by Rome Therapeutics
- ROME Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference – ROME Therapeutics
- ROME Therapeutics Appoints Heike Keilhack, Ph.D., as Chief Scientific Officer – ROME Therapeutics
- ROME Publishes Landmark Nature Paper Revealing First High-Resolution Structure of LINE-1 Reverse Transcriptase (RT) for Drug Discovery – ROME Therapeutics
- ROME Therapeutics Presents First Data to Validate LINE-1 RT as a Novel Target in Autoimmune Diseases and the Therapeutic Potential of its First-in-Class LINE-1 RT Inhibitors – ROME Therapeutics
- Enara Bio, ROME Therapeutics and Nucleome Therapeutics to Host 2nd Annual Dark Genome Symposium – ROME Therapeutics
- ROME Expands Leadership Team with the Appointment of Industry Veteran Kyle Kuvalanka as Chief Financial Officer and Chief Business Officer – ROME Therapeutics
- ROME Therapeutics Closes Oversubscribed $72 Million Series B Extension to Support Advancement of Lead Program into Clinical Development for Autoimmune Disease – ROME Therapeutics
- ROME Therapeutics Appoints Keith Wilcoxen, Ph.D., as Executive Vice President, Early Development – ROME Therapeutics
- ROME Therapeutics Demonstrates Efficacy of its Novel LINE-1 Reverse Transcriptase Inhibitor in Translational Models of Autoimmune Disease – ROME Therapeutics
- ROME Therapeutics and Enara Bio to Host Inaugural Dark Genome Symposium Convening Industry and Academic Leaders to Catalyze Therapeutic Application of Dark Genome Research – ROME Therapeutics
- View more press releases Close
Social media about Rome Therapeutics
- Rome Therapeutics on Wikipedia, Google News & Yahoo Finance
- Rome Therapeutics on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Rosana Kapeller 
Call Rome Therapeutics at +1 617...
